{
  "concept": "Glucose limitation may fundamentally reprogram TNF receptor complex assembly by altering the balance between TRAF2/cIAP1 and RIPK1 recruitment through differential ubiquitination patterns. This metabolic reprogramming could redirect cellular responses from necroptotic death toward NF-κB-mediated survival. Such findings suggest that metabolic thresholds in tumor microenvironments may serve as molecular switches that determine whether death receptor signaling promotes therapeutic cell elimination or treatment resistance.",
  "rationale": [
    {
      "statement": "TNF receptor signaling operates through a critical molecular divergence point where specific ubiquitination patterns determine cell fate. The recruitment of TRAF2 and cIAP1 promotes pro-survival NF-κB activation, while RIPK1-mediated complex formation triggers necroptotic cell death. This ubiquitination-dependent switch represents the fundamental mechanism through which metabolic signals could reprogram death receptor outcomes.",
      "supporting_dois": [
        "10.1016/j.cell.2013.05.014",
        "10.1016/j.celrep.2015.11.009",
        "10.1016/j.heliyon.2024.e28092",
        "10.1016/j.molcel.2018.01.027",
        "10.1038/cdd.2016.78",
        "10.1038/cddis.2011.111",
        "10.1038/cddis.2015.158",
        "10.1038/s41418-020-00629-3",
        "10.1038/s41419-024-07325-x",
        "10.1038/s41467-019-11839-w",
        "10.1038/s41467-020-19935-y",
        "10.1073/pnas.93.24.13973",
        "10.1074/jbc.m109.072256",
        "10.1074/jbc.m109.076976",
        "10.1074/jbc.m110.216226",
        "10.1074/jbc.m112.347195",
        "10.1074/jbc.m504019200",
        "10.1074/jbc.m600620200",
        "10.1126/science.281.5383.1680",
        "10.1128/mcb.00048-14"
      ]
    },
    {
      "statement": "Cellular energy status directly controls ubiquitination machinery through ATP-dependent enzymatic activities. E3 ligases and deubiquitinases require sufficient energy resources for optimal function, creating a direct mechanistic link between glucose availability and protein ubiquitination patterns that regulate TNF receptor complex assembly.",
      "supporting_dois": [
        "10.1007/s10495-021-01706-9",
        "10.1016/s0014-5793(97)00721-7",
        "10.1038/cdd.2016.78",
        "10.1038/cddis.2013.464",
        "10.1038/s41419-023-06014-5",
        "10.1074/jbc.m504019200",
        "10.1074/jbc.m513562200",
        "10.1091/mbc.e08-03-0328",
        "10.1158/1538-7445.sabcs18-4442",
        "10.1158/2159-8290.cd-22-1230",
        "10.1186/1476-4598-10-57",
        "10.18632/oncotarget.2042",
        "10.2337/db18-2465-pub",
        "10.3390/ijms23031536"
      ]
    },
    {
      "statement": "Multiple lines of empirical evidence demonstrate that glucose levels correlate with shifts in death receptor signaling outcomes. Glucose deprivation enhances TNF-induced apoptosis across tumor cell lines, while high-glucose conditions can trigger necroptotic pathways. Additionally, NF-κB inhibition switches TNF responses from proliferation to necroptotic death, confirming the competitive relationship between survival and death pathways.",
      "supporting_dois": [
        "10.1002/ijc.2910520310",
        "10.1002/jcp.21885",
        "10.1038/msb.2012.20",
        "10.1074/jbc.m110.166702",
        "10.1074/jbc.m212392200",
        "10.1089/jir.1996.16.1021",
        "10.1111/jfbc.13810",
        "10.1126/science.274.5288.784",
        "10.1155/2023/2713864",
        "10.1158/0008-5472.can-12-2460",
        "10.1159/000529995",
        "10.1371/journal.pone.0000340",
        "10.1371/journal.pone.0036775",
        "10.2337/db20-24-lb",
        "10.2485/jhtb.31.187",
        "10.26508/lsa.202000956",
        "10.3389/fphar.2022.966645",
        "10.3390/ijms24108609"
      ]
    },
    {
      "statement": "Tumor microenvironments present complex metabolic stresses beyond glucose limitation, including hypoxia and reliance on alternative metabolic pathways. These conditions similarly reprogram ubiquitination landscapes and alter TNF pathway outcomes, suggesting that metabolic reprogramming of death receptor signaling represents a broadly applicable mechanism in cancer biology.",
      "supporting_dois": [
        "10.1007/s12672-025-02032-1",
        "10.1016/j.canlet.2018.05.017",
        "10.1038/s41418-020-00629-3",
        "10.1038/s41419-019-1504-6",
        "10.1038/s41419-020-2449-5",
        "10.1038/s41419-022-05008-z",
        "10.1038/s41419-024-07325-x",
        "10.1038/s41467-018-02951-4",
        "10.1038/s41467-019-10374-y",
        "10.1042/bj20021279",
        "10.1042/bj20080476",
        "10.1073/pnas.080072497",
        "10.1074/jbc.m109.072256",
        "10.1074/jbc.m110.216226",
        "10.1074/jbc.m600620200",
        "10.1080/23723556.2019.1644599",
        "10.1084/jem.20040624",
        "10.1091/mbc.e02-09-0598",
        "10.1091/mbc.e07-04-0391",
        "10.1128/mcb.00773-08",
        "10.1128/mcb.01416-12",
        "10.1158/1541-7786.mcr-20-0579",
        "10.1177/1947601910382901",
        "10.1186/2049-3002-1-23",
        "10.1242/dmm.017285",
        "10.1371/journal.pcbi.1010690",
        "10.14800/ics.792",
        "10.3389/fendo.2022.970843",
        "10.3389/fonc.2012.00005",
        "10.3390/biom10030411",
        "10.7150/ijbs.69882",
        "10.7554/elife.62394"
      ]
    },
    {
      "statement": "Advanced experimental approaches provide the technical foundation to investigate this metabolic reprogramming hypothesis. High-resolution imaging techniques, mass spectrometry-based interactomics, and real-time monitoring systems enable precise mapping of ubiquitination changes and protein complex dynamics under metabolic stress conditions.",
      "supporting_dois": [
        "10.1002/0471140864.ps1925s79",
        "10.1002/0471142956.cy1210s42",
        "10.1002/0471143030.cb0421s41",
        "10.1002/cbf.4007",
        "10.1002/pmic.200401000",
        "10.1002/rcm.3227",
        "10.1016/j.csbj.2019.04.009",
        "10.1021/jacs.9b03418",
        "10.1021/pr070520u",
        "10.1021/pr700734f",
        "10.1038/s41418-020-00629-3",
        "10.1038/s41467-020-19935-y",
        "10.1038/s41598-021-00098-9",
        "10.1039/c7nr03454g",
        "10.1039/d0cc02252g",
        "10.1046/j.0022-2720.2001.00984.x",
        "10.1073/pnas.0807705105",
        "10.1074/mcp.m112.017905",
        "10.1093/bib/bbv052",
        "10.1093/bioinformatics/btm397",
        "10.1096/fasebj.2020.34.s1.04631",
        "10.1101/pdb.top086249",
        "10.1126/scisignal.abn1101",
        "10.1177/2211068214560608",
        "10.1186/1471-2105-13-s16-s6",
        "10.1186/s12915-018-0554-z",
        "10.1364/biomed.2012.btu1a.2",
        "10.1364/boe.6.000277",
        "10.1364/omp.2013.mth1c.5",
        "10.1371/journal.pone.0036535",
        "10.14712/fb2010056020066",
        "10.18632/oncotarget.24323",
        "10.3389/fchem.2019.00816",
        "10.3390/molecules28052283",
        "10.3791/57902",
        "10.3791/57902-v",
        "10.3791/61602-v"
      ]
    },
    {
      "statement": "Clinically relevant model systems, including patient-derived organoids and glycolysis-dependent cancer cell lines, provide appropriate platforms for studying metabolic thresholds in death receptor signaling. These models capture the genetic and metabolic heterogeneity of human tumors while enabling controlled investigation of glucose-dependent signaling reprogramming.",
      "supporting_dois": [
        "10.1002/ijc.2910520310",
        "10.1002/jcp.24346",
        "10.1002/path.3978",
        "10.1002/viw.20240127",
        "10.1016/j.molmet.2020.101093",
        "10.1016/j.neo.2019.04.004",
        "10.1016/j.neo.2024.100985",
        "10.1038/s41467-019-08759-0",
        "10.1038/s41598-020-70396-1",
        "10.1073/pnas.1219555110",
        "10.1073/pnas.1516689112",
        "10.1073/pnas.202474099",
        "10.1074/jbc.m212392200",
        "10.1093/noajnl/vdad152",
        "10.1096/fj.202300649r",
        "10.1097/cm9.0000000000002477",
        "10.1109/embc.2018.8512784",
        "10.1126/scitranslmed.aau7377",
        "10.1128/mcb.18.5.2845",
        "10.1155/2021/8886050",
        "10.1158/0008-5472.can-12-1572-t",
        "10.1158/1078-0432.ccr-15-2274",
        "10.1158/1078-0432.ccr-18-3590",
        "10.1159/000217977",
        "10.3389/fmolb.2021.752404",
        "10.3389/fonc.2020.00553",
        "10.3390/cancers12123869"
      ]
    },
    {
      "statement": "Understanding metabolic control of death receptor signaling offers significant therapeutic potential. Targeting tumor-specific metabolic vulnerabilities could enforce pro-death outcomes in nutrient-deprived microenvironments, potentially overcoming treatment resistance mechanisms while minimizing effects on healthy tissues with different metabolic profiles.",
      "supporting_dois": [
        "10.1002/1873-3468.14623",
        "10.1002/adma.202311043",
        "10.1002/bies.201400085",
        "10.1002/cbin.12160",
        "10.1016/j.tranon.2019.11.011",
        "10.1038/s41467-019-10374-y",
        "10.1038/s41467-024-52973-4",
        "10.1038/s43018-022-00393-y",
        "10.1080/15384101.2015.1056947",
        "10.1080/2162402x.2016.1149673",
        "10.1126/sciadv.abg7287",
        "10.1158/1538-7445.crc22-a015",
        "10.1158/2159-8290.cd-22-1230",
        "10.2174/1876390101103010042",
        "10.3389/fonc.2012.00005",
        "10.4049/jimmunol.198.supp.73.25",
        "10.54254/2753-8818/2025.gu20971"
      ]
    }
  ]
}